Modified Psilocin Derivative May Treat Depression Without Inducing Hallucinogenic Side Effects in Early Trials

ACS researchers create modified psilocin that treats depression and brain disorders without the hallucinations, potentially making treatment safer for patients.

By: AXL Media

Published: Mar 8, 2026, 6:42 AM EDT

Engineering a Non-Hallucinogenic Therapeutic

Scientists are pioneering a new approach to harness the neuroplasticity benefits of psychedelics by decoupling their therapeutic activity from their mind-altering side effects. A team led by the American Chemical Society has designed modified versions of psilocin, the active metabolite of psilocybin found in magic mushrooms. These engineered molecules are specifically intended to treat depression, anxiety, and neurodegenerative conditions like Alzheimer’s disease. By modifying the chemical structure, researchers believe they can offer the rapid-acting relief associated with psychedelics while removing the barriers created by intense hallucinations, which often limit the clinical application and patient acceptance of these treatments.

Targeting Serotonin Pathways for Brain Health

The cornerstone of this research lies in the relationship between serotonin receptors and mood regulation. Many brain disorders are rooted in disrupted serotonin signaling, and psilocin is known to interact strongly with these pathways to promote neural connectivity. The research team, including authors Andrea Mattarei and Sara De Martin, created five chemical variants designed to release psilocin into the brain at a more controlled, steady pace. This slow-release strategy aims to preserve the "biological activity" necessary for repairing neural circuits while avoiding the rapid chemical surge that typically triggers a psychedelic experience.

Laboratory Validation of the 4e Candidate

During preliminary laboratory testing, researchers utilized human plasma and simulated gastrointestinal environments to identify the most stable compound among the five variants. A specific derivative known as 4e emerged as the leading candidate due to its high stability and its ability to cross the blood-brain barrier efficiently. Experimental data confirmed that 4e activated key serotonin receptors at levels comparable to pharmaceutical-grade psilocybin. However, unlike traditional psilocybin, the 4e compound provided a longer-lasting but lower-intensity presence in the brain, suggesting a more manageable pharmacokinetic profile for potential human use.